- Home
- BMRN vs MBLY Comparison
BMRN vs MBLY Comparison
Compare BMRN & MBLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BMRN
- MBLY
- Stock Information
- Founded
- BMRN 1996
- MBLY 1999
- Country
- BMRN United States
- MBLY Israel
- Employees
- BMRN N/A
- MBLY N/A
- Industry
- BMRN Biotechnology: Pharmaceutical Preparations
- MBLY Computer Software: Prepackaged Software
- Sector
- BMRN Health Care
- MBLY Technology
- Exchange
- BMRN Nasdaq
- MBLY Nasdaq
- Market Cap
- BMRN 12.1B
- MBLY 11.8B
- IPO Year
- BMRN 1999
- MBLY 2022
- Fundamental
- Price
- BMRN $55.00
- MBLY $14.72
- Analyst Decision
- BMRN Buy
- MBLY Buy
- Analyst Count
- BMRN 22
- MBLY 20
- Target Price
- BMRN $93.43
- MBLY $19.33
- AVG Volume (30 Days)
- BMRN 2.2M
- MBLY 3.1M
- Earning Date
- BMRN 08-04-2025
- MBLY 07-31-2025
- Dividend Yield
- BMRN N/A
- MBLY N/A
- EPS Growth
- BMRN 152.82
- MBLY N/A
- EPS
- BMRN 2.71
- MBLY N/A
- Revenue
- BMRN $2,950,227,000.00
- MBLY $1,853,000,000.00
- Revenue This Year
- BMRN $12.23
- MBLY $8.77
- Revenue Next Year
- BMRN $9.99
- MBLY $16.40
- P/E Ratio
- BMRN $20.29
- MBLY N/A
- Revenue Growth
- BMRN 19.36
- MBLY N/A
- 52 Week Low
- BMRN $52.93
- MBLY $10.48
- 52 Week High
- BMRN $94.85
- MBLY $28.73
- Technical
- Relative Strength Index (RSI)
- BMRN 35.12
- MBLY 40.57
- Support Level
- BMRN $54.46
- MBLY $15.75
- Resistance Level
- BMRN $58.17
- MBLY $16.90
- Average True Range (ATR)
- BMRN 1.39
- MBLY 0.68
- MACD
- BMRN -0.04
- MBLY -0.23
- Stochastic Oscillator
- BMRN 13.08
- MBLY 3.91
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
About MBLY Mobileye Global Inc.
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. The company's reportable operating segment are Mobileye and Others. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System & Vehicles. It derives maximum revenue from Mobileye Segment.